Semprus BioSciences is a venture-funded biomedical company whose proprietary rationally designed polymeric system organizes, manages and harnesses water molecules on a medical device surface. This system creates a highly non-fouling performance that significantly reduces attachment of proteins, cells, bacteria and other biological matter. The company’s products are designed to reduce the 56,000 preventable annual U.S. deaths and $11.2 billion cost of infection and thrombus-related complications1 that often arise when medical devices are implanted in the body.
Dr. Loose has led the establishment of the company’s proprietary Semprus Sustain™ Technology since co-founding the company with David Lucchino in 2007. Prior to this, he earned his Ph.D. in Chemical Engineering at the Massachusetts Institute of Technology (MIT) under the guidance of Professors Robert Langer, Sc. D., and Gregory Stephanopoulos, Ph.D. Dr. Loose began his career working for Merck Research Labs.
Dr. Loose has previously been selected by Technology Review as a member of the TR35, representing 35 leaders under 35 years old most likely to impact the future of technology, and received the Hertz Foundation Fellowship, awarded to 15 of the top doctoral students in the U.S. across all applied sciences.
“All of us at Semprus are incredibly proud of Chris and are glad his talents are being recognized by the entire Boston community,” said Chief Executive Officer David L. Lucchino. “It’s impressive to see how Chris has utilized his exceptional scientific problem solving skills as Semprus is on the verge of delivering a solution to address large unmet clinical needs.” Dr. Loose will be recognized along with his fellow honorees at an evening reception limited to 400 at the State Room in Downtown Boston on Thursday, October 6. The reception will be sponsored by JetBlue Airways.
1 Journal of Wound Care, February 2010 (Wilcott et al.), Chronic Wounds and the Medical Biofilm Paradigm.
About Semprus BioSciences
Semprus BioSciences is a venture-backed biomedical company headquartered in Cambridge, Massachusetts. The company’s innovative, proprietary Semprus Sustain™ Technology signifies a breakthrough in medical device technology with its highly non-fouling surface using covalently bonded polymers that coordinate water over the device surface to give extended durability. In December 2010, the company completed an $18 million Series B financing co-led by SR One, the corporate venture capital arm of GlaxoSmithKline, and Foundation Medical Partners (FMP), a national healthcare venture capital investment firm with a strategic relationship with Cleveland Clinic. Combined with previous financing rounds, Semprus has raised a total of $28.5 million in equity.
